0001062993-24-003168.txt : 20240214
0001062993-24-003168.hdr.sgml : 20240214
20240214161442
ACCESSION NUMBER: 0001062993-24-003168
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240212
FILED AS OF DATE: 20240214
DATE AS OF CHANGE: 20240214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Thomas B
CENTRAL INDEX KEY: 0001748462
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37372
FILM NUMBER: 24638339
MAIL ADDRESS:
STREET 1: BIODELIVERY SCIENCES INTERNATIONAL, INC.
STREET 2: 4131 PARKLAKE AVE SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC
CENTRAL INDEX KEY: 0001267565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: VA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
BUSINESS PHONE: 781-713-3699
MAIL ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
FORMER COMPANY:
FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC
DATE OF NAME CHANGE: 20031020
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-02-12
0001267565
COLLEGIUM PHARMACEUTICAL, INC
COLL
0001748462
Smith Thomas B
C/O COLLEGIUM PHARMACEUTICAL, INC.
100 TECHNOLOGY CENTER DRIVE
STOUGHTON
MA
02072
0
1
0
0
EVP and Chief Medical Officer
0
Common Stock
2024-02-12
4
A
0
30800
0
A
62980
D
Common Stock
2024-02-12
4
A
0
4623
0
A
67603
D
Common Stock
2024-02-12
4
F
0
1899
33.70
D
65704
D
Common Stock
2024-02-12
4
F
0
1300
33.70
D
64404
D
Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
Includes 442 and 553 shares acquired on each of July 21, 2023 and January 19, 2024, respectively, under the Issuer's employee stock purchase plan.
Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 4,623 performance share units ("PSUs") granted in the Issuer's prior fiscal year.
Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.
Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.
/s/ Colleen Tupper as Attorney-In-Fact For Thomas B. Smith, MD
2024-02-14